Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Afghani Children Suffering From Post Traumatic Stress
Children who live in Afghanistan are particularly affected every day by a multitude of war time stressors which increase the likelihood of developing PTSD: trauma, child labor, and family and military violence. On a daily basis they are first-hand witnesses to the bombings, abuse, and the general upheaval of their home life and society as a result of war, including the effects of long-term poverty and familial turmoil.
generic viagra online
RCP's Response To Lord Darzi's Report, High Quality Care For All, Our Journey So Far.
Responding to the publication of High Quality Care for All, Our journey so far, Professor Ian Gilmore, President of the Royal College of Physicians, said Drugshop to buy zoloft online and other pills.
News of the day
International Collaboration By Scientists Culminates In Novel Ion Channels Database
An important re consolidating understanding of the roles played by Ion channels in drug action is now available for scientists and students.
Sexual Health

Cellceutix Files Patent Application For Its Cancer Compound

Cellceutix Corporation (OTCBB: CTIX), announced it has filed a U.S. patent application covering pharmaceutical formulations of a compound referred to as Kevetrin™ and many novel compounds having similar structures to Kevetrin. These structures cover a large number of compounds that Cellceutix can look at as possible drug development candidates. The application covers the use of Kevetrin™ and the other compounds in various areas, including cancers. Cellceutix plans to file in other countries within a year of the U.S. filing. George Evans, CEO stated: "This is a very exciting time for Cellceutix. The compounds covered by this patent application are structurally very different from anti-cancer agents currently on the market. Quite frankly, it took us longer than we expected to file this patent application due to the additional compounds that presented themselves as Kevetrin™ related structures. The result is a patent with new and expanded claims that will provide a strong intellectual property base for Kevetrin and a large portfolio of possible compounds for future development. In the meantime, we"ve been doing some very interesting experiments with Kevetrin and with our psoriasis candidate, KM-133. We anticipate announcing study results over the coming weeks." Cellceutix


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009